Benitec Biopharma (NASDAQ:BNTC) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Benitec Biopharma (NASDAQ:BNTC) posted its earnings results on Friday. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02, FiscalAI reports.

Benitec Biopharma Price Performance

Shares of BNTC traded down $0.05 on Friday, reaching $9.04. The company’s stock had a trading volume of 144,689 shares, compared to its average volume of 196,941. The stock’s 50 day simple moving average is $9.67 and its two-hundred day simple moving average is $11.39. The stock has a market capitalization of $315.40 million, a P/E ratio of -9.22 and a beta of 0.26. Benitec Biopharma has a 12-month low of $7.89 and a 12-month high of $14.39.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Wall Street Zen cut Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Wedbush lifted their price objective on Benitec Biopharma from $16.00 to $17.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. Royal Bank Of Canada upgraded Benitec Biopharma to an “outperform” rating in a research report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Thursday, October 15th. Finally, HC Wainwright reissued a “buy” rating on shares of Benitec Biopharma in a report on Monday, November 2nd. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.00.

Benitec Biopharma Company Profile

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company’s lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.